LT3458478T - Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui - Google Patents

Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui

Info

Publication number
LT3458478T
LT3458478T LTEP17726862.0T LT17726862T LT3458478T LT 3458478 T LT3458478 T LT 3458478T LT 17726862 T LT17726862 T LT 17726862T LT 3458478 T LT3458478 T LT 3458478T
Authority
LT
Lithuania
Prior art keywords
cancer treatment
lag3 antibodies
lag3
antibodies
cancer
Prior art date
Application number
LTEP17726862.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Markus Zettl
Ivo Lorenz
Otmar Schaaf
Melanie WURM
Jean-François FORTIN
Scott Brodeur
Keith A. Canada
Lukasz CHLEWICKI
Pankaj Gupta
Priyanka Gupta
Rocio K. PEREZ
Joseph Robert WOSKA JR.
Haiguang Xiao
Danlin YANG
Walter Carroll Davidson
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of LT3458478T publication Critical patent/LT3458478T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP17726862.0T 2016-05-18 2017-05-17 Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui LT3458478T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16170174 2016-05-18
PCT/EP2017/061901 WO2017198741A1 (en) 2016-05-18 2017-05-17 Anti pd-1 and anti-lag3 antibodies for cancer treatment

Publications (1)

Publication Number Publication Date
LT3458478T true LT3458478T (lt) 2021-02-10

Family

ID=56014918

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17726862.0T LT3458478T (lt) 2016-05-18 2017-05-17 Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui

Country Status (31)

Country Link
US (3) US11028169B2 (de)
EP (2) EP3458478B1 (de)
JP (3) JP6585860B2 (de)
KR (2) KR20220103806A (de)
CN (2) CN109415439B (de)
AR (1) AR108516A1 (de)
AU (1) AU2017266298B2 (de)
BR (1) BR112018072986A2 (de)
CA (1) CA3020649A1 (de)
CL (2) CL2018003153A1 (de)
CO (1) CO2018012374A2 (de)
CY (1) CY1123977T1 (de)
DK (1) DK3458478T3 (de)
EA (1) EA201892616A1 (de)
ES (1) ES2857813T3 (de)
HU (1) HUE053452T2 (de)
IL (1) IL262892B2 (de)
LT (1) LT3458478T (de)
MA (2) MA55697A (de)
MX (2) MX2018014102A (de)
MY (1) MY193112A (de)
PE (1) PE20190108A1 (de)
PH (1) PH12018502429A1 (de)
PL (1) PL3458478T3 (de)
RS (1) RS61510B1 (de)
SA (1) SA518400424B1 (de)
SG (1) SG11201809627QA (de)
SI (1) SI3458478T1 (de)
TW (2) TWI762484B (de)
UA (1) UA127200C2 (de)
WO (1) WO2017198741A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000621A (es) 2015-07-13 2018-05-11 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
KR102194188B1 (ko) 2015-11-18 2020-12-24 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
DK3458478T3 (da) 2016-05-18 2021-03-22 Boehringer Ingelheim Int Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CN117567622A (zh) 2016-10-13 2024-02-20 正大天晴药业集团股份有限公司 抗lag-3抗体及组合物
EA201991214A1 (ru) 2016-11-18 2019-10-31 Антитела против pd-1 и их композиции
EP3360898A1 (de) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
EP4116328A1 (de) 2017-04-05 2023-01-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Kombinationstherapien, die auf pd-1, tim-3, and lag-3 abzielen
WO2018185135A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
EP4245375A3 (de) 2017-05-30 2023-12-06 Bristol-Myers Squibb Company Zusammensetzungen mit einer kombination aus einem anti-lag-3-antikörper, einem pd-1-signalweginhibitor und einem immuntherapeutikum
KR20200010501A (ko) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
CA3065304A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
CN110691790A (zh) * 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
US20220031842A1 (en) * 2017-12-22 2022-02-03 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody pharmaceutical composition and use thereof
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
EP3746119A4 (de) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. Verfahren zur behandlung von krebs oder infektionen unter verwendung einer kombination eines anti-pd-1-antikörpers, eines anti-lag3-antikörpers und eines anti-tigit-antikörpers
WO2019165195A1 (en) * 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
EP3774840A1 (de) 2018-03-27 2021-02-17 Bristol-Myers Squibb Company Echtzeitüberwachung der proteinkonzentration mittels ultraviolettem signal
AU2019266205A1 (en) 2018-05-07 2020-10-22 Genmab A/S Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
EP3569618A1 (de) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisierender cd73-antikörper
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3802922B1 (de) * 2018-06-11 2023-04-26 Yale University Neue immuncheck-inhibitoren
US20210238287A1 (en) 2018-07-26 2021-08-05 Bristol-Myers Squibb Company LAG-3 Combination Therapy for the Treatment of Cancer
CN113286611A (zh) 2018-10-19 2021-08-20 百时美施贵宝公司 用于黑色素瘤的组合疗法
JP2022512866A (ja) * 2018-11-05 2022-02-07 メルク・シャープ・アンド・ドーム・コーポレーション がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
US20210380694A1 (en) 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112021008873A8 (pt) * 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
TW202043466A (zh) 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
US11578129B2 (en) * 2019-03-29 2023-02-14 Boehringer Ingelheim International Gmbh LRP5 and PD-1 antagonist anticancer combination therapy
US20220249659A1 (en) * 2019-05-13 2022-08-11 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
EP3973274A1 (de) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Verfahren zur überwachung von zellkulturmedien
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
EP3983450A4 (de) * 2019-06-12 2023-07-05 Nanjing GenScript Biotech Co., Ltd. Anti-pd-l1-/anti-lag-3-proteine mit mehrfacher antigenbindung und verfahren zu ihrer verwendung
CN112121169B (zh) * 2019-06-24 2023-10-24 广州再极医药科技有限公司 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JPWO2021025140A1 (de) 2019-08-08 2021-02-11
TW202114637A (zh) * 2019-08-22 2021-04-16 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ｐｄ－１抗體ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
KR20220066334A (ko) 2019-09-22 2022-05-24 브리스톨-마이어스 스큅 컴퍼니 Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
JP2022553851A (ja) 2019-11-08 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー 黒色腫の処置のためのｌａｇ－３アンタゴニスト
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
US20230087600A1 (en) 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
EP4161544A1 (de) 2020-06-03 2023-04-12 Boehringer Ingelheim International GmbH Rekombinantes rhabdovirus, das für ein fc-fusionsprotein der extrazellulären domäne cd80 codiert
CN111808192B (zh) * 2020-06-05 2022-02-15 北京天广实生物技术股份有限公司 结合lag3的抗体及其用途
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
WO2022047189A1 (en) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
BR112023005377A2 (pt) 2020-09-24 2023-04-25 Merck Sharp & Dohme Llc Formulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e variantes de hialuronidase e fragmentos das mesmas e métodos de uso das mesmas
EP4225770A1 (de) 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Verfahren zur konzentration von proteinen
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
IL302836A (en) 2020-11-17 2023-07-01 Seagen Inc Methods for treating cancer with a combination of tocatinib and an anti-PD-1/anti-PD-L1 antibody
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
MX2023007734A (es) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Composiciones de anticuerpos y metodos de uso de las mismas.
EP4267172A1 (de) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subkutane verabreichung von pd1/pd-l1-antikörpern
WO2022212400A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
EP4337694A1 (de) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3- und gal3-hemmer, xbp1, cs1 und cd138-peptide und verfahren zur verwendung davon
TW202317625A (zh) 2021-06-17 2023-05-01 德商百靈佳殷格翰國際股份有限公司 新穎三特異性結合分子
KR20240046323A (ko) 2021-07-13 2024-04-08 비온테크 에스이 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against PD-L1 and CD137 in combination
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023077090A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023183317A2 (en) * 2022-03-21 2023-09-28 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024013315A1 (en) 2022-07-15 2024-01-18 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
CN115960834B (zh) * 2023-03-07 2023-06-09 浙江省肿瘤医院 一种pd-1/ptx联合pd-1耐药模型建立的方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DK0701571T3 (da) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antistoffragmenter til terapi
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2288994C (en) 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US20040010134A1 (en) 2000-04-12 2004-01-15 Rosen Craig A. Albumin fusion proteins
EP2706116A1 (de) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Bindungsdomäne-Immunglobulin-Fusionsproteine
EP1456410A2 (de) 2001-12-11 2004-09-15 AlgoNomics N.V. Vefahren für die ausstellung von loops aus immunogloblin-domänen
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
EP2390268B1 (de) 2002-11-08 2017-11-01 Ablynx N.V. Gegen Tumornekrosefaktor-alpha gerichtete Einzeldomänen-Antikörper und Verwendungen dafür
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
ATE414106T1 (de) 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP3508497A1 (de) 2012-05-24 2019-07-10 Mountgate Group Limited Zusammensetzungen und verfahren in zusammenhang mit der vorbeugung und behandlung von tollwutinfektion
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP6224739B2 (ja) * 2013-03-15 2017-11-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 抗ｌａｇ−３結合タンパク質
SG11201508528TA (en) * 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
HUE062317T2 (hu) * 2013-09-20 2023-10-28 Bristol Myers Squibb Co Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez
JP6535337B2 (ja) * 2013-11-05 2019-06-26 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法
SG10201804945WA (en) * 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CU24481B1 (es) * 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
AU2015294834B2 (en) * 2014-07-31 2021-04-29 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN113577264A (zh) 2015-04-17 2021-11-02 百时美施贵宝公司 包含抗pd-1抗体和另外的抗体的组合的组合物
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
DK3458478T3 (da) 2016-05-18 2021-03-22 Boehringer Ingelheim Int Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling

Also Published As

Publication number Publication date
CL2021002094A1 (es) 2022-04-08
KR20220103806A (ko) 2022-07-22
CN109415439A (zh) 2019-03-01
ES2857813T3 (es) 2021-09-29
US20240124581A1 (en) 2024-04-18
TWI762484B (zh) 2022-05-01
EP3848393A1 (de) 2021-07-14
JP2020007340A (ja) 2020-01-16
AU2017266298B2 (en) 2024-01-04
IL262892B1 (en) 2023-12-01
TW202307002A (zh) 2023-02-16
CA3020649A1 (en) 2017-11-23
JP2019522460A (ja) 2019-08-15
CL2018003153A1 (es) 2019-01-18
EP3458478B1 (de) 2021-01-06
EA201892616A1 (ru) 2019-05-31
HUE053452T2 (hu) 2021-07-28
PE20190108A1 (es) 2019-01-15
IL262892B2 (en) 2024-04-01
PL3458478T3 (pl) 2021-06-28
IL262892A (en) 2018-12-31
CN115340608A (zh) 2022-11-15
DK3458478T3 (da) 2021-03-22
MA55697A (fr) 2022-02-23
CN109415439B (zh) 2022-10-04
CO2018012374A2 (es) 2018-11-30
TW201806974A (zh) 2018-03-01
BR112018072986A2 (pt) 2019-03-06
EP3458478A1 (de) 2019-03-27
KR20190006177A (ko) 2019-01-17
US11795219B2 (en) 2023-10-24
JP6585860B2 (ja) 2019-10-02
MX2018014102A (es) 2019-04-29
MY193112A (en) 2022-09-26
SG11201809627QA (en) 2018-12-28
SI3458478T1 (sl) 2021-04-30
JP2019050804A (ja) 2019-04-04
JP6585801B2 (ja) 2019-10-02
US20210095020A1 (en) 2021-04-01
UA127200C2 (uk) 2023-06-07
MA45029A (fr) 2019-03-27
KR102419412B1 (ko) 2022-07-12
MX2022008184A (es) 2022-08-02
AR108516A1 (es) 2018-08-29
MA45029B1 (fr) 2021-03-31
SA518400424B1 (ar) 2022-08-17
RS61510B1 (sr) 2021-03-31
US20170334995A1 (en) 2017-11-23
PH12018502429A1 (en) 2019-09-30
AU2017266298A1 (en) 2018-10-25
WO2017198741A1 (en) 2017-11-23
US11028169B2 (en) 2021-06-08
CY1123977T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
IL262892A (en) Anti-pd-1 and anti-lag3 antibodies for cancer therapy
HK1252272A1 (zh) 使用抗ox40抗體治療癌症的方法
HK1251474A1 (zh) 使用抗ox40抗體和pd-1軸結合拮抗劑治療癌症的方法
IL265541B1 (en) Bispecific antibodies and compounds containing them for the treatment of cancer
IL263178A (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
HK1247848A1 (zh) 抗pd-1和抗m-csf抗體在治療癌症中的聯合應用
HK1251862A1 (zh) 治療癌症的方法和組合物
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
EP3426777A4 (de) Kombinationsvektoren und verfahren zur behandlung von krebs
EP3177292A4 (de) Verbindungen und verwendung zur behandlung von krebs
IL260474B (en) Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment
EP3589659A4 (de) Verbindungen und verwendung zur behandlung von krebs
EP3119427A4 (de) Verfahren und materialien zur behandlung von krebs
ZA201802618B (en) Anti-cd43 antibody and use thereof for cancer treatment
EP3119426A4 (de) Verfahren und materialien zur behandlung von krebs
EP3697767A4 (de) Verbindungen und verwendung zur behandlung von krebs
EP3568145A4 (de) Materialien und verfahren zur behandlung von krebs
EP3303289A4 (de) Verbindungen und verwendung zur behandlung von krebs
EP3273970A4 (de) Verfahren und materialien zur behandlung von krebs
GB2571036B (en) Aglycosylated antibody Fc region for treating cancer
PT3458478T (pt) Anticorpos anti pd-1 e anti-lag3 para tratamento de cancro
GB201720089D0 (en) Means and methods for treating cancer
EP3615074A4 (de) Verfahren und materialien zur behandlung von krebs
EP3481803A4 (de) Verfahren und materialien zur behandlung von krebs